Bladder dysfunction in diabetes mellitus

Frontiers in Pharmacology

Volumn 1 NOV, Issue , 2010, Pages

  Golbidi, Saeid ^a   Laher, Ismail ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cystopathy; Diabetes; Incontinence; Neurogenic bladder

Indexed keywords

EID: 79956203552     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2010.00136     Document Type: Article

References (97)

1. Abrams, P., Andersson, K. E., Buccafusco, J. J., Chapple, C., de Groat, W. C., Fryer, A. D., Kay, G., Laties, A., Nathanson, N. M., Pasricha, P. J., and Wein, A. J. (2006). Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br. J. Pharmacol. 148, 565-578.
2. Apodaca, G. (2004). The uroepithelium: not just a passive barrier. Traffic 5, 117-128.
3. Apodaca, G., Kiss, S., Ruiz, W., Meyers, S., Zeidel, M., and Birder, L. (2003). Disruption of bladder epithelium barrier function after spinal cord injury. Am. J. Physiol. Renal Physiol. 284, F966-F976.
4. Beshay, E., and Carrier, S. (2004). Oxidative stress plays a role in diabetes-induced bladder dysfunction in a rat model. Urology 64, 1062-1067.
5. Biastre, K., and Burnakis, T. (2009). Trospium chloride treatment of overactive bladder. Ann. Pharmacother. 43, 283-295.
6. Birder, L. A., and de Groat, W. C. (2007). Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat. Clin. Pract. Urol. 4, 46-54.
7. Birder, L. A., Nakamura, Y., Kiss, S., Nealen, M. L., Barrick, S., Kanai, A. J., Wang, E., Ruiz, G., De Groat, W. C., Apodaca, G., Watkins, S., and Caterina, M. J. (2002a). Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat. Neurosci. 5, 856-860.
8. Birder, L. A., Nealen, M. L., Kiss, S., de Groat, W. C., Caterina, M. J., Wang, E., Apodaca, G., and Kanai, A. J. (2002b). Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J. Neurosci. 22, 8063-8070.
9. Birnbaum, H., Leong, S., and Kabra, A. (2003). Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence. Womens Health Issues 13, 204-213.
10. Brady, C. M., Apostolidis, A., Yiangou, Y., Baecker, P. A., Ford, A. P., Freeman, A., Jacques, T. S., Fowler, C. J., and Anand, P. (2004). P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur. Urol. 46, 247-253.
11. Brown, J. S., Wessells, H., Chancellor, M. B., Howards, S. S., Stamm, W. E., Stapleton, A. E., Steers, W. D., Van Den Eeden, S. K., and McVary, K. T. (2005). Urologic complications of diabetes. Diabetes Care 28, 177-185.
12. Brown, J. S., Wing, R., Barrett-Connor, E., Nyberg, L. M., Kusek, J. W., Orchard, T. J., Ma, Y., Vittinghoff, E., Kanaya, A. M., and Diabetes Prevention Program Research Group. (2006). Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care 29, 385-390.
13. Burnstock, G. (2001). Purine-mediated signalling in pain and visceral perception. Trends Pharmacol. Sci. 22, 182-188.
14. Changolkar, A. K., Hypolite, J. A., Disanto, M., Oates, P. J., Wein, A. J., and Chacko, S. (2005). Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase. J. Urol. 173, 309-313.
15. Chapple, C. R., Fianu-Jonsson, A., Indig, M., Khullar, V., Rosa, J., Scarpa, R. M., Mistry, A., Wright, D. M., Bolodeoku, J., and STAR Study Group. (2007). Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur. Urol. 52, 1195-1203.
16. Chapple, C., Khullar, V., Gabriel, Z., and Dooley, J. A. (2005). The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur. Urol. 48, 5-26.
17. Coffin, R. S., MacLean, A. R., Latchman, D. S., and Brown, S. M. (1996). Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors. Gene Ther. 3, 886-891.
18. Daneshgari, F., Liu, G., Birder, L., Hanna-Mitchell, A. T., and Chacko, S. (2009). Diabetic bladder dysfunction: current translational knowledge. J. Urol. 182, S18-S26.
19. Daneshgari, F., Liu, G., and Imrey, P. B. (2006). Time dependent changes in diabetic cystopathy in rats include compensated and decompensated bladder function. J. Urol. 176, 380-386.
20. Daneshgari, F., and Moy, M. L. (2005). Current indications for neuromodulation. Urol. Clin. North Am. 32, 37-40.
21. Daniels, D. H., Powell, C. R., Braasch, M. R., and Kreder, K. J. (2010). Sacral neuromodulation in diabetic patients: success and complications in the treatment of voiding dysfunction. Neurourol. Urodyn. 29, 578-581.
22. Duby, J. J., Campbell, R. K., Setter, S. M., White, J. R., and Rasmussen, K. A. (2004). Diabetic neuropathy: an intensive review. Am. J. Health Syst. Pharm. 61, 160-173.
23. Ellsworth, P. (2009). Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther. Clin. Risk Manag. 5, 869-876.
24. Fedele, D. (2005). Therapy insight: sexual and bladder dysfunction associated with diabetes mellitus. Nat. Clin. Pract. Urol. 2, 282-290.
25. Fink, D. J., DeLuca, N. A., Goins, W. F., and Glorioso, J. C. (1996). Gene transfer to neurons using herpes simplex virus-based vectors. Annu. Rev. Neurosci. 19, 265-287.
26. Forbes, J. M., Coughlan, M. T., and Cooper, M. E. (2008). Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57, 1446-1454.
27. Frimodt-Møller, C. (1978). Diabetic cystopathy. A review of the urodynamic and clinical features of neurogenic bladder dysfunction in diabetes mellitus. Dan. Med. Bull. 25, 49-60.
28. Frimodt-Møller, C. (1980). Diabetic cystopathy: epidemiology and related disorders. Ann. Intern. Med. 92, 318-321.
29. Frimodt-Møller, C., and Mortensen, S. (1980). Treatment of diabetic cystopathy. Ann. Intern. Med. 92, 327-328.
30. Geerlings, S. E., Meiland, R., van Lith, E. C., Brouwer, E. C., Gaastra, W., and Hoepelman, A. I. (2002). Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: more in diabetic women than in control subjects. Diabetes Care 25, 1405-1409.
31. Giannitsas, K., Perimenis, P., Athanasopoulos, A., Gyftopoulos, K., Nikiforidis, G., and Barbalias, G. (2004). Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. Eur. Urol. 46, 776-782.
32. Goins, W. F., Lee, K. A., Cavalcoli, J. D., O'Malley, M. E., DeKosky, S. T., Fink, D. J., and Glorioso, J. C. (1999). Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J. Virol. 73, 519-532.
33. Goldman, H. B., and Appell, R. A. (1999). Voiding dysfunction in women with diabetes mellitus. Int. Urogynecol. J. Pelvic Floor Dysfunct. 10, 130-133.
34. Haab, F. (2000). Discussion: nitric oxide and bladder overactivity. Urology 55, 58-59.
35. Hegde, S. S. (2006). Muscarinic receptors in the bladder: from basic research to therapeutics. Br. J. Pharmacol. 147, S80-S87.
36. Hellweg, R., and Hartung, H. D. (1990). Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J. Neurosci. Res. 26, 258-267.
37. Herbison, P., Hay-Smith, J., Ellis, G., and Moore, K. (2003). Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326, 841-844.
38. Hill, S. R., Fayyad, A. M., and Jones, G. R. (2008). Diabetes mellitus and female lower urinary tract symptoms: a review. Neurourol. Urodyn. 27, 362-367.
39. Ho, C. H., Tai, H. C., and Yu, H. J. (2010). Urodynamic findings in female diabetic patients with and without overactive bladder symptoms. Neurourol. Urodyn. 29, 424-427.
40. Ho, M. H., Bhatia, N. N., and Khorram, O. (2004). Physiologic role of nitric oxide and nitric oxide synthase in female lower urinary tract. Curr. Opin. Obstet. Gynecol. 16, 423-429.
41. Ho, M. H., Yip, S., and Bhatia, N. N. (2007). Lower urinary tract dysfunctions in women with diabetes mellitus. Curr. Opin. Obstet. Gynecol. 19, 469-473.
42. Hunsballe, J. M., and Djurhuus, J. C. (2001). Clinical options for imipramine in the management of urinary incontinence. Urol. Res. 29, 118-125.
43. Hunter, K. F., and Moore, K. N. (2003). Diabetes-associated bladder dysfunction in the older adult (CE). Geriatr. Nurs. 24, 138-145.
44. Junemann, K. P., and Al-Shukri, S. (2000). Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge syndrome: a double blind, placebo controlled multicenter clinical trial. Neurourol. Urodyn. 19, 488-493.
45. Kaplan, S. A., Te, A. E., and Blaivas, J. G. (1995). Urodynamic findings in patients with diabetic cystopathy. J. Urol. 153, 342-344.
46. Kebapci, N., Yenilmez, A., Efe, B., Entok, E., and Demirustu, C. (2007). Bladder dysfunction in type 2 diabetic patients. Neurourol. Urodyn. 26, 814-819.
47. Kitami, K. (1991). Vesicourethral dysfunction of diabetic patients. Nippon Hinyokika Gakkai Zasshi 82, 1074-1083.
48. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., Nathan, D. M., and Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403.
49. Kubota, Y., Nakahara, T., Mitani, A., Maruko, T., Sakamoto, K., and Ishii, K. (2003). Augmentation of rat urinary bladder relaxation mediated by beta1-adrenoceptors in experimental diabetes. Eur. J. Pharmacol. 467, 191-195.
50. Lee, K. S., Lee, H. W., Choo, M. S., Paick, J. S., Lee, J. G., Seo, J. T., Lee, J. Z., Lee, Y. S., Yoon, H., Park, C. H., Na, Y. G., Jeong, Y. B., Lee, J. B., and Park, W. H. (2010). Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU Int. 105, 1565-1570.
51. Lee, W. C., Wu, H. P., Tai, T. Y., Liu, S. P., Chen, J., and Yu, H. J. (2004). Effects of diabetes on female voiding behavior. J. Urol. 172, 989-992.
52. Levi-Montalcini, R. (1987). The nerve growth factor 35 years later. Science 237, 1154-1162.
53. Mamas, M. A., Reynard, J. M., and Brading, A. F. (2003). Nitric oxide and the lower urinary tract: current concepts, future prospects. Urology 61, 1079-1085.
54. Manning, J., Korda, A., Benness, C., and Solomon, M. (2003). The association of obstructive defecation, lower urinary tract dysfunction and the benign joint hypermobility syndrome: a casecontrol study. Int. Urogynecol. J. Pelvic Floor Dysfunct. 14, 128-132.
55. Michel, M. C., de la Rosette, J. J., Piro, M., and Goepel, M. (2004). Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? J. Urol. 172, 601-604.
56. Michel, M. C., and Vrydag, W. (2006). Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br. J. Pharmacol. 147, S88-S119.
57. Moore, K. N., Saltmarche, B., and Query, A. (2003). Urinary incontinence. Non-surgical management by family physicians. Can. Fam. Physician 49, 602-610.
58. Mumtaz, F. H., Khan, M. A., Thompson, C. S., Morgan, R. J., and Mikhailidis, D. P. (2000). Nitric oxide in the lower urinary tract: physiological and pathological implications. BJU Int. 85, 567-578.
59. Novara, G., Galfano, A., Secco, S., D'Elia, C., Cavalleri, S., Ficarra, V., and Artibani, W. (2008). A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur. Urol. 54, 740-763.
60. Parsons, C. L. (1994). The therapeutic role of sulfated polysaccharides in the urinary bladder. Urol. Clin. North Am. 21, 93-100.
61. Peters, S. L., Schmidt, M., and Michel, M. C. (2006). Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol. Sci. 27, 492-497.
62. Pinna, C., Bolego, C., and Puglisi, L. (1994). Effects of substance P and capsaicin on urinary bladder of diabetic rat and the role of the epithelium. Eur. J. Pharmacol. 271, 151-158.
63. Pinna, C., Zanardo, R., and Puglisi, L. (2000). Prostaglandin-release impairment in the bladder epithelium of streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 388, 267-273.
64. Rapidi, C. A., Karandreas, N., Katsifotis, C., Benroubi, M., Petropoulou, K., and Theodorou, C. (2006). A combined urodynamic and electrophysi ological study of diabetic cystopathy. Neurourol. Urodyn. 25, 32-38.
65. Raz, S., Kaufman, J. J., Ellison, G. W., and Mayers, L. W. (1977). Methyldopa in treatment of neurogenic bladder disorders. Urology 9, 188-190.
66. Reitz, A., Bretscher, S., Knapp, P. A., Müntener, M., Wefer, B., and Schurch, B. (2004). The effect of nitric oxide on the resting tone and the contractile behaviour of the external urethral sphincter: a functional urodynamic study in healthy humans. Eur. Urol. 45, 367-373.
67. Saito, M., Kinoshita, Y., Satoh, I., Shinbori, C., Suzuki, H., Yamada, M., Watanabe, T., and Satoh, K. (2007). Ability of cyclohexenonic long-chain fatty alcohol to reverse diabetes-induced cystopathy in the rat. Eur. Urol. 51, 479-487.
68. Saito, M., and Miyagawa, I. (2002). N(G)-nitro-l-arginine methylester, a nitric oxide synthase inhibitor, diminishes apoptosis induced by ischemia-reperfusion in the rat bladder. Neurourol. Urodyn. 21, 566-571.
69. Saito, M., Nakamura, I., and Miyagawa, I. (1997). Autoradiographic localization of muscarinic receptors in diabetic rat bladder. Nippon Hinyokika Gakkai Zasshi 88, 858-867.
70. Satriano, J. (2007). Kidney growth, hypertrophy and the unifying mechanism of diabetic complications. Amino Acids 33, 331-339.
71. Schilling, J. D., and Hultgren, S. J. (2002). Recent advances into the pathogenesis of recurrent urinary tract infections: the bladder as a reservoir for uropathogenic Escherichia coli. Int. J. Antimicrob. Agents 19, 457-460.
72. Shamliyan, T. A., Kane, R. L., Wyman, J., and Wilt, T. J. (2008). Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Ann. Intern. Med. 148, 459-473.
73. Smith, D. B. (2006). Urinary incontinence and diabetes: a review. J. Wound Ostomy Continence Nurs. 33, 619-623.
74. Stapleton, A. (2002). Urinary tract infections in patients with diabetes. Am. J. Med. 113(Suppl. 1A), 80S-84S.
75. Starer, P., and Libow, L. (1990). Cystometric evaluation of bladder dysfunction in elderly diabetic patients. Arch. Intern. Med. 150, 810-813.
76. Steers, W. D., and Tuttle, J. B. (2006). Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat. Clin. Pract. Urol. 2, 101-110.
77. Subak, L. L., Johnson, C., Whitcomb, E., Boban, D., Saxton, J., and Brown, J. S. (2002). Does weight loss improve incontinence in moderately obese women? Int. Urogynecol. J. Pelvic Floor Dysfunct. 13, 40-43.
78. Suzuki, H., Saito, M., Kinoshita, Y., Satoh, I., Kono, T., ShinBori, C., Anastasios, S., Yamada, M., and Satoh, K. (2006). Preventive effects of cyclohexenonic long-chain fatty alcohol on diabetic cystopathy in the rat. Can. J. Physiol. Pharmacol. 84, 195-201.
79. Tammela, T. (1986). Prevention of prolonged voiding problems after unexpected postoperative urinary retention: comparison of phenoxybenzamine and carbachol. J. Urol. 136, 1254-1257.
80. Tammela, T. L., Briscoe, J. A., Levin, R. M., and Longhurst, P. A. (1994). Factors underlying the increased sensitivity to field stimulation of urinary bladder strips from streptozotocin-induced diabetic rats. Br. J. Pharmacol. 113, 195-203.
81. Thoenen, H., and Barde, Y. A. (1980). Physiology of nerve growth factor. Physiol. Rev. 60, 1284-1335.
82. Tominaga, M., Wada, M., and Masu, M. (2001). Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc. Natl. Acad. Sci. U.S.A. 98, 6951-6956.
83. Tong, Y. C., and Cheng, J. T. (2007). Aldose reductase inhibitor ONO-2235 restores the alterations of bladder nerve growth factor and neurotrophin receptor p75 genetic expression in streptozotocin induced diabetic rats. J. Urol. 178, 2203-2207.
84. Tong, Y. C., Chin, W. T., and Cheng, J. T. (1999). Alterations in urinary bladder M2-muscarinic receptor protein and mRNA in 2-week streptozotocininduced diabetic rats. Neurosci. Lett. 277, 173-176.
85. Tzefos, M., Dolder, C., and Olin, J. L. (2009). Fesoterodine for the treatment of overactive bladder. Ann. Pharmacother. 43, 1992-2000.
86. Ueda, T., Yoshimura, N., and Yoshida, O. (1997). Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response. J. Urol. 157, 580-584.
87. Van Poppel, H., Stessens, R., Van Damme, B., Carton, H., and Baert, L. (1998). Diabetic cystopathy: neuropathological examination of urinary bladder biopsies. Eur. Urol. 15, 128-131.
88. Wakabayashi, Y., Maeda, T., and Kwok, Y. N. (1996). Increase of p75 immunoreactivity in rat urinary bladder following inflammation. Neuroreport 7, 1141-1144.
89. Wakabayashi, Y., Tomoyoshi, T., Tooyama, I., Kitahama, K., Kim, S. U., and Maeda, T. (1995). Low-affinity nerve growth factor receptor immunoreactivity in the human urinary bladder. Neurosci. Lett. 186, 9-12.
90. Wang, E. C., Lee, J. M., Ruiz, W. G., Balestreire, E. M., von Bodungen, M., Barrick, S., Cockayne, D. A., Birder, L. A., and Apodaca, G. (2005). ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. J. Clin. Invest. 115, 2412-2422.
91. Waring, J. V., and Wendt, I. R. (2000). Effects of streptozotocin-induced diabetes mellitus on intracellular calcium and contraction of longitudinal smooth muscle from rat urinary bladder. J. Urol. 163, 323-330.
92. Wein, A. J., Van Arsdalen, K., and Levin, R. M. (1992). "Pharmacologic therapy," in Clinical Neuro-Urology, eds R. J. Krane and M. B. Siroky (Boston: Little Brown and Company), 523-557.
93. Yenilmez, A., Ozçifçi, M., Aydin, Y., Turgut, M., Uzuner, K., and Erkul, A. (2006). Protective effect of high-dose thiamine (B1) on rat detrusor contractility in streptozotocin-induced diabetes mellitus. Acta Diabetol. 43, 103-108.
94. Yoshimura, N., Chancellor, M. B., Andersson, K. E., and Christ, G. J. (2005). Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int. 95, 733-738.
95. Zenser, T. V., Thomasson, D. L., and Davis, B. B. (1988). Characteristics of bradykinin and TPA increases in the PGE2 levels of human urothelial cells. Carcinogenesis 9, 1173-1177.
96. Ziegler, D. (2001). Diagnosis and treatment of diabetic autonomic neuropathy. Curr. Diab. Rep. 1, 216-227.
97. Zincke, H., Campbell, J. T., Palumbo, P. J., and Furlow, W. L. (1974). Neurogenic vesical dysfunction in diabetes mellitus: another look at vesical neck resection. J. Urol. 111, 488-490.